Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jan 25;12(1):576.
doi: 10.1038/s41467-020-20443-2.

Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder

Collaborators, Affiliations
Meta-Analysis

Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder

Ditte Demontis et al. Nat Commun. .

Erratum in

Abstract

Attention-Deficit/Hyperactivity Disorder (ADHD) is a childhood psychiatric disorder often comorbid with disruptive behavior disorders (DBDs). Here, we report a GWAS meta-analysis of ADHD comorbid with DBDs (ADHD + DBDs) including 3802 cases and 31,305 controls. We identify three genome-wide significant loci on chromosomes 1, 7, and 11. A meta-analysis including a Chinese cohort supports that the locus on chromosome 11 is a strong risk locus for ADHD + DBDs across European and Chinese ancestries (rs7118422, P = 3.15×10-10, OR = 1.17). We find a higher SNP heritability for ADHD + DBDs (h2SNP = 0.34) when compared to ADHD without DBDs (h2SNP = 0.20), high genetic correlations between ADHD + DBDs and aggressive (rg = 0.81) and anti-social behaviors (rg = 0.82), and an increased burden (polygenic score) of variants associated with ADHD and aggression in ADHD + DBDs compared to ADHD without DBDs. Our results suggest an increased load of common risk variants in ADHD + DBDs compared to ADHD without DBDs, which in part can be explained by variants associated with aggressive behavior.

PubMed Disclaimer

Conflict of interest statement

Ditte Demontis has received speaking fee from Takeda. Barbara Franke has received educational speaking fees from Medice. Benjamin M. Neale is a member of the scientific advisory board at Deep Genomics and consultant for Camp4 Therapeutics, Takeda Pharmaceutical and Biogen.

Figures

Fig. 1
Fig. 1. Manhattan plot and quantile–quantile plot of results from the GWAS meta-analysis of ADHD + DBDs.
A Results from GWAS meta-analysis of iPSYCH and PGC cohorts in total including 3802 cases and 31,305 controls. The x-axis represents autosomal chromosomes colored in light and dark blue. The y-axis represents two-sided P-values from meta-analysis using an inverse-variance weighted fixed effects model. The red horizontal line represents the threshold for genome-wide significant association (P = 5 × 10−8). B Quantile–quantile (q–q) plot with expected −log10 P-values on the x-axis and −log10 P-values from the GWAS meta-analysis on the y-axis. The dotted line indicates the distribution under the null hypothesis.
Fig. 2
Fig. 2. Forest plot for the index variant in the genome-wide significant locus for ADHD + DBDs on chromosome 11.
Forest plot for the index variant (rs7118422) in the genome-wide significant locus on chromosome 11. Visualization of the effect size estimates (natural logarithm of the odds ratio (ln(OR)) in each included cohort, estimated from logistic regression, and in the trans-ancestry GWAS meta-analysis of European and Chinese cohorts (4208 cases and 32,222 controls) using an inverse-variance weighted fixed effects model. In addition, standard errors of the ln(OR) estimates. For information on sample sizes, allele frequencies and P-values for rs7118422 in the single cohorts see Supplementary Data 1.

References

    1. Faraone, S. V. et al. Attention-deficit/hyperactivity disorder. Nat. Rev. Dis. Primers1, 15020 (2015). - PubMed
    1. Franke B, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur. Neuropsychopharmacol. 2018;28:1059–1088. doi: 10.1016/j.euroneuro.2018.08.001. - DOI - PMC - PubMed
    1. Fairchild G, et al. Conduct disorder. Nat. Rev. Dis. Primers. 2019;5:43. doi: 10.1038/s41572-019-0095-y. - DOI - PubMed
    1. Canino G, Polanczyk G, Bauermeister JJ, Rohde LA, Frick PJ. Does the prevalence of CD and ODD vary across cultures? Soc. Psychiatry Psychiatr. Epidemiol. 2010;45:695–704. doi: 10.1007/s00127-010-0242-y. - DOI - PMC - PubMed
    1. Nock MK, Kazdin AE, Hiripi E, Kessler RC. Lifetime prevalence, correlates, and persistence of oppositional defiant disorder: results from the National Comorbidity Survey Replication. J. Child Psychol. Psychiatry. 2007;48:703–713. doi: 10.1111/j.1469-7610.2007.01733.x. - DOI - PubMed

Publication types

MeSH terms